1. On 09/26/2025, the U.S. Court of International Trade issued a statutory injunction (SI) enjoining liquidation of entries identified in paragraph 2 which are subject to the antidumping duty order on glycine from India (A-533-883) for the period 06/01/2022 through 05/31/2023. This SI was issued in connection with court number 25-00081. 2. This SI enjoins liquidation of entries of glycine from India that were exported by Kumar Industries and Bajaj Healthcare Limited, that were the subject of the United States Department of Commerce's final determination in Glycine from India; Final Results of Antidumping Duty Administrative Review; 2022-2023, 90 Fed. Reg. 15689 (Apr. 15, 2025), and that were entered, or withdrawn from warehouse, for consumption, during the period 06/01/2022 through 05/31/2023. 3. Effective 09/26/2025 (the date the Court issued the SI), no liquidation may be made for entries referred to in paragraph 2 which remain unliquidated as of 09/26/2025. Any such entries that are set for liquidation must be unset immediately. Continue to suspend liquidation of these entries until liquidation instructions are issued. 4. Effective immediately, CBP is instructed to follow the terms of the SI. 5. The SI applies to the liquidation instructions in message number 5143409, dated 05/23/2025. 6. If there are any questions by the importing public regarding this message, please contact the Call Center for the Office of AD/CVD Operations, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce at (202) 482-0984. CBP ports should submit their inquiries through authorized CBP channels only. (This message was generated by OVI:TRW.) 7. There are no restrictions on the release of this information. Alexander Amdur